BioAuxilium Research Launches New THUNDER™ TR-FRET Biomarker Assay Kits and an Enhanced Assay Development Service for Drug Discovery
27.2.2023 19:00:00 EET | Business Wire | Press release
At the annual Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in San Diego, BioAuxilium Research Inc., a biotech tool company focused on facilitating access to fully validated assay kits to the biomedical research community, today announced the expansion of its no-wash THUNDER™ time-resolved Förster resonance energy transfer (TR-FRET) technology portfolio by introducing six new biomarker research assay kits, a Reader Control Kit, and an enhanced assay development service for drug discovery research.
BioAuxilium developed the new biomarker assays in response to customer requests for reliable cell-based assays that provide an alternative to expensive immunoassay platforms such as other TR‑FRET and bead-based assay technologies. The new offerings include a panel of six key mouse inflammatory cytokines (CCL-2/MCP1, IFN-beta, IFN-gamma, IL-2, IL-6, and TNF-alpha), expanding the company’s portfolio to a total of 100 cell-based assay kits (76 Cell Signaling Kinases, 23 Biomarkers, and a cAMP Assay). The ready-to-use Reader Control Kit allows users to assess in just 10 minutes the suitability of TR‑FRET compatible microplate readers to perform Europium-based TR-FRET measurements.
The new assay development service offers three types of custom assay solutions: labeling of antibodies with BioAuxilium’s proprietary TR-FRET fluorophores, custom assay development services, and custom kit development services. These comprehensive, yet flexible custom solutions are designed to fast-track assay development, while further reducing risk, turnaround time, and cost.
“BioAuxilium continues to make great strides with the expansion of the THUNDER™ TR-FRET technology portfolio, based on customer demand for high-performing, reliable yet affordable immunoassays,” said Jaime Padros, PhD, President, BioAuxilium Research. “In addition, our decades of experience developing and manufacturing drug discovery assays based on TR-FRET allow us to deliver results within turnaround times and at prices simply unattainable by any other custom assay development service.”
BioAuxilium’s THUNDER™ TR-FRET technology is a robust, proprietary platform based on a FRET pair showing an enhanced spectral compatibility and TR-FRET signal, best antibody pairs selected specifically for TR-FRET, and a panel of optimized lysis and assay buffers. In addition, the “add-incubate-read” protocol of the immunoassay platform, combined with its full compatibility with different TR-FRET readers, facilitates streamlined workflows and automation for high-throughput screening. All THUNDER™ TR-FRET assays are extensively validated to ensure specificity, sensitivity, reproducibility, and lot-to-lot consistency.
About BioAuxilium Research Inc.
BioAuxilium is a private Canadian biotechnology tool company founded by expert assay scientists. It focuses on developing and manufacturing top-quality, highly validated assay kits that accelerate drug discovery and basic research. BioAuxilium’s kits are based on its enhanced proprietary THUNDER™ TR‑FRET technology. They are offered at an outstanding value and are accompanied by information-rich datasheets and expert technical support. BioAuxilium also provides customized services in assay development on a contract basis. Their products and services are available directly to US- and Canada-based customers, and through the company’s network of international distributors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005027/en/
Contact information
Jaime Padros, President
514-312-9033 ext. 101
jaime.padros@bioauxilium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 19:25:00 EET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of
Positive Phase 3 Data Demonstrate Potential for ENTYVIO ® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 19:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), show vedolizumab’s promising efficacy and safety profile in a patient population where therapy options remain limited.With KEPLER, Takeda is continuing to generate deeper scientific insights and identify additional patient populations who may benefit from vedolizumab, a cornerstone therapy for adults with ulcerative colitis. Vedolizumab is marketed under the trade name ENTYVIO®*. “Ulcerative colitis is a life-altering diagnosis for young patients and their families, often leaving t
Andersen Consulting Broadens Built-Asset Advisory Through Collaboration with Grinity19.2.2026 16:30:00 EET | Press release
Andersen Consulting has entered into a Collaboration Agreement with Grinity, a built-asset consultancy delivering technical, environmental, and sustainable development services to construction and real estate markets. Operating across the Czech Republic and Slovakia with more than 130 professionals, Grinity serves private and public clients in commercial development, industry, technology, automotive, and sustainability. The firm provides multidisciplinary expertise in project and cost management, technical advisory, transactional services, ESG consulting, and energy optimization for buildings. “Sustainability has become a strategic imperative, but clients also need integrated delivery across scope, cost, schedule, risk, and quality,” said Pavel Čermák, CEO of Grinity. “By combining our project and cost management, technical advisory, and energy optimization expertise with Andersen’s global platform, we can deliver comprehensive, forward-looking solutions that drive long-term value for
Fosway 9-Grid™ Analysis Identifies O.C. Tanner as Strategic Leader in the Talent & People Success Market19.2.2026 16:00:00 EET | Press release
O.C. Tanner, the global leader in employee recognition and culture solutions, is honored to be recognized once again as a Strategic Leader in the latest Fosway 9-Grid™ for Talent & People Success. This top industry placement from Fosway Group, Europe’s leading HR and talent analyst, reaffirms O.C. Tanner’s ongoing commitment to innovating employee engagement and workplace culture. Fosway’s independent analysis positions vendors based on performance, potential, market presence, total cost of ownership, and trajectory, helping HR leaders make informed decisions about workplace solutions. O.C. Tanner’s recognition reflects both the strength of its Culture Cloud® platform and its ability to support complex, enterprise-level needs with meaningful outcomes. “Being named a Strategic Leader by Fosway is a powerful validation of the impact our team is delivering for organizations around the world,” said Scott Sperry, President and CEO of O.C. Tanner. “Today’s talent environment demands culture-
Visa Renews Partnership Across Red Bull Formula One Teams19.2.2026 16:00:00 EET | Press release
Visa (NYSE: V) today announced a multi‑year renewal and expansion of its global partnership with Red Bull F1 Team’s Oracle Red Bull Racing and Visa Cash App Racing Bulls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219542270/en/ Building on the groundbreaking partnership launched in 2024, the renewed agreement reinforces Visa’s commitment to one of the world’s fastest‑growing sports, while introducing significant new branding rights, enhanced hospitality assets and immersive experiential opportunities across both teams. Visa will also continue as a Title Partner of both Visa Cash App Racing Bulls Formula One Team and its F1 Academy Programme, further strengthening Visa’s presence on and off the grid. “This renewal reflects the extraordinary momentum we’ve built with Red Bull Racing Teams, Visa Cash App Racing Bulls and Oracle Red Bull Racing, and our shared ambition to push what’s possible at the intersection of sport,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom